Compare

BioCryst/$BCRX

1D1W1M3M6MYTD1Y5YMAX

About BioCryst

BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
Ticker
$BCRX
Sector
Health
Primary listing
NASDAQ
Employees
435

BioCryst Metrics

BasicAdvanced
$1.9B
-
-$1.49
0.51
-

What the Analysts think about BioCryst

Analyst ratings (Buy, Hold, Sell) for BioCryst stock.
Analyst projections of the future price of BioCryst stock.

Bulls say / Bears say

ORLADEYO remains a growth engine: comparable third-quarter sales rose 20% year on year, and oral pellets extend the treatment to children while giving older patients another formulation choice. The FDA approved the pellets for patients aged 12 and above in October. (BioCryst Pharmaceuticals)
BioCryst is showing operating leverage, with third-quarter operating profit rising to $53.3 million from $29.6 million a year earlier. It also cut its 2026 operating-expense outlook and expects the Birmingham closure to deliver $30 million to $35 million in annual savings once fully realised. (BioCryst Pharmaceuticals)
The pipeline offers a possible second growth driver: navenibart’s pivotal HAE trial is fully enrolled, with results expected in the third quarter of 2027 and dosing planned every three or six months. BioCryst also expects initial patient data this year from its early-stage Netherton syndrome candidate, BCX17725. (BioCryst Pharmaceuticals)
A stronger oral rival could erode ORLADEYO’s advantage: Pharvaris reported Phase 3 results for deucrictibant showing an 83% reduction in HAE attacks versus placebo, and RBC cut its BioCryst rating while estimating ORLADEYO sales could eventually fall to $400 million–$450 million. (Yahoo Finance)
Third-quarter ORLADEYO revenue got a one-off boost from CareMed’s initial inventory build, which management estimated at the upper teens of millions of dollars. The company kept its ORLADEYO sales guidance unchanged, so reported growth may overstate the underlying run rate during the pharmacy transition. (The Motley Fool)
BioCryst’s financing obligations are substantial: at September 30 it had $400 million of secured term loans and $426.8 million of royalty financing obligations, against $376.4 million in cash and investments. That debt and royalty burden may limit flexibility if sales weaken or pipeline investment needs rise. (StockTitan)
Data summarised monthly by Lightyear AI. Last updated on 6 Nov 2026.

BioCryst Financial Performance

Revenues and expenses
Income statement
AnnuallyQuarterly
2023
YoY growth
Revenue
Net income
Profit margin

BioCryst Earnings Performance

Company profitability
Earnings per share
AnnuallyQuarterly
2020
2021
2022
2023
2024
Actual
Expected
Surprise
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.